查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451670

2024-2032 年按类型、疾病类型、技术、配销通路和地区分類的治疗性疫苗市场报告

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2023年全球治疗性疫苗市场规模达到313亿美元。展望未来， IMARC Group预计到2032年市场规模将达到714亿美元，2024-2032年复合年增长率（CAGR）为9.5%。治疗选择有限的疾病盛行率不断上升，个人对微创手术（MIS）的偏好不断增加，以及製药公司、研究机构和学术界之间不断加强的合作伙伴关係是推动市场的一些主要因素。

治疗性疫苗，也称为治疗疫苗或免疫疗法疫苗，是一种旨在刺激患者免疫系统针对和对抗特定疾病的医疗干预措施。与化疗等传统疗法相比，它们的副作用更少。它们刺激免疫系统而不会对健康细​​胞造成广泛损害。它们有助于降低初始治疗后疾病復发的可能性。它们可以与其他治疗方法（例如化疗或标靶治疗）结合使用，以产生协同效应。它们透过增强免疫反应来控制病毒量并最大限度地减少疾病进展，从而帮助管理人类免疫缺陷病毒 (HIV) 和乙型肝炎等慢性感染。

治疗选择有限的疾病（例如某些类型的癌症和罕见疾病）的盛行率不断上升，正在催化对疫苗等创新治疗方法的需求。此外，人口老化日益严重，极易患各种慢性疾病，这推动了对治疗性疫苗等新型治疗方式的需求。除此之外，各国政府正在为免疫疗法和疫苗领域的研发提供支持性政策、补助和资金。此外，个人对非侵入性或微创治疗方案的日益偏好正在推动对治疗性疫苗的需求。此外，製药公司、研究机构和学术界之间的合作正在加速治疗性疫苗的开发和商业化。

治疗疫苗市场趋势/驱动因素：

慢性病盛行率上升

癌症、自体免疫疾病和传染病等各种慢性健康状况的盛行率不断上升，是推动市场成长的关键因素之一。治疗性疫苗透过利用个体的免疫系统来识别和靶向疾病相关抗原，提供了一条有前途的途径。除此之外，对个人化药物日益增长的偏好正在对市场产生正面影响。这些疫苗有潜力针对特定疾病并彻底改变疾病管理。此外，治疗性疫苗可以降低疾病復发的风险，并提高患者的治疗效果和生活品质。

免疫学和生物技术的进步

免疫学和生物技术的快速进步正在创造积极的市场前景。这些科学进步正在重新定义我们对免疫系统及其对疾病反应的理解。此外，免疫学的突破揭示了免疫检查点、细胞激素讯号传导和抗原呈现的复杂性，为推动更有效的治疗性疫苗的开发提供了见解。除此之外，生物技术创新，包括基于 mRNA 的疫苗平台和基因编辑技术，正在重新构想疫苗设计和生产的格局。此外，基于奈米颗粒的疫苗的出现提供了控制抗原呈现的机会，放大了免疫反应以提高治疗效果。

转向精准医疗

向精准医疗的转变正在积极影响治疗性疫苗市场。精准医学体现了以患者为中心的方法，根据个别特征（如遗传学、分子谱和免疫标记）客製化治疗方案。这种方法承认每位患者疾病的独特性，并寻求优化治疗结果。除此之外，这些疫苗透过针对每位患者独特的疾病特异性抗原来解决癌症等疾病固有的异质性。预测性生物标记的识别和创新生物标记引导策略的引入提高了积极反应的可能性，因为它们确定了最有可能从这些治疗中受益的患者。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球治疗疫苗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 抗原疫苗
    • 市场走向
    • 市场预测
  • 树突细胞疫苗
    • 市场走向
    • 市场预测
  • DNA疫苗
    • 市场走向
    • 市场预测
  • 肿瘤细胞疫苗
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依疾病类型

  • 自体免疫疾病疫苗
    • 市场走向
    • 市场预测
  • 成瘾疫苗
    • 市场走向
    • 市场预测
  • 神经系统疾病疫苗
    • 市场走向
    • 市场预测
  • 传染病疫苗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依技术

  • 自体疫苗
    • 市场走向
    • 市场预测
  • 同种异体疫苗
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Agenus Inc.
    • Argos Therapeutics Inc.
    • Bavarian Nordic A/S
    • Cel-Sci Corporation
    • CSL Limited
    • Emergent Biosolutions Inc.
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A6496

The global therapeutic vaccines market size reached US$ 31.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 71.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.5% during 2024-2032. The rising prevalence of diseases with limited treatment options, increasing preferences of individuals for minimally invasive surgeries (MIS), and the growing partnerships between pharmaceutical companies, research institutions, and academia are some of the major factors propelling the market.

Therapeutic vaccines, also known as treatment vaccines or immunotherapeutic vaccines, are a type of medical intervention designed to stimulate the immune system of patients to target and combat specific diseases. They have fewer side effects compared to traditional treatments like chemotherapy. They stimulate the immune system without causing extensive damage to healthy cells. They help reduce the likelihood of disease recurrence after initial treatment. They can be combined with other treatments, such as chemotherapy or targeted therapies, to create a synergistic effect. They aid in managing chronic infections like human immunodeficiency viruses (HIV) and hepatitis B by enhancing the immune response to control the viral load and minimize disease progression.

The rising prevalence of diseases with limited treatment options, such as certain types of cancers and rare disorders, is catalyzing the demand for innovative therapeutic approaches like vaccines. Additionally, the increasing aging population aging population, which is highly susceptible to various chronic ailments is driving the need for novel treatment modalities like therapeutic vaccines. Apart from this, governments of various countries are offering supportive policies, grants, and funding for research and development (R&D) in the field of immunotherapy and vaccines. Furthermore, the rising preferences of individuals for non-invasive or minimally invasive treatment options are driving the demand for therapeutic vaccines. Moreover, partnerships between pharmaceutical companies, research institutions, and academia are accelerating the development and commercialization of therapeutic vaccines.

Therapeutic Vaccines Market Trends/Drivers:

Rising prevalence of chronic diseases

The rising prevalence of various chronic health conditions, such as cancer, autoimmune disorders, and infectious diseases represents one of the key factors propelling the market growth. Therapeutic vaccines offer a promising avenue by harnessing the immune system of individuals to recognize and target disease-associated antigens. Apart from this, rising preferences for personalized medicines is positively influencing the market. These vaccines hold the potential to target specific disorders and revolutionize disease management. Moreover, therapeutic vaccines can reduce the risk of disease recurrence, enhancing patient outcomes and quality of life.

Advancements in immunology and biotechnology

The rapid advancements in immunology and biotechnology are creating a positive market outlook. These scientific advancements are redefining our understanding of the immune system and its responses to diseases. Additionally, breakthroughs in immunology are unveiling the intricacies of immune checkpoints, cytokine signaling, and antigen presentation, providing insights that fuel the development of more effective therapeutic vaccines. Apart from this, biotechnology innovations, including mRNA-based vaccine platforms and gene editing techniques, are reimagining the landscape of vaccine design and production. Furthermore, the advent of nanoparticle-based vaccines offers opportunities for controlled antigen presentation, amplifying the immune reaction for heightened therapeutic efficacy.

Shift towards precision medicine

The shift towards precision medicine is positively influencing the therapeutic vaccines market. Precision medicine embodies a patient-centric approach, tailoring treatments to individual characteristics such as genetics, molecular profiles, and immunological markers. This approach acknowledges the uniqueness of the disease of each patient and seeks to optimize therapeutic outcomes. Apart from this, these vaccines address the inherent heterogeneity of diseases like cancer by targeting disease-specific antigens that are distinct to each patient. The identification of predictive biomarkers and the introduction of innovative biomarker-guided strategies enhance the likelihood of positive responses, as they identify patients who are most likely to benefit from these treatments.

Therapeutic Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global therapeutic vaccines market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, disease type, technology and distribution channel.

Breakup by Type:

Antigen Vaccines

Dendritic Cell Vaccine

DNA Vaccine

Tumor Cell Vaccines

Tumor cell vaccines hold the largest market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes antigen vaccines, dendritic cell vaccine, DNA vaccine, and tumor cell vaccines. According to the report, tumor cell vaccines represented the largest market segment as they are specifically designed to target cancer cells, offering a highly focused approach to treatment. This specificity minimizes damage to healthy cells, reducing adverse effects commonly associated with traditional therapies. Additionally, they stimulate the immune system to remember cancer cells, enabling the body to respond more effectively if the cancer recurs. This immune memory contributes to longer-lasting treatment outcomes. Apart from this, they can be used in combination with other treatments like checkpoint inhibitors or chemotherapy, creating a synergistic effect that enhances the overall treatment response. Furthermore, these vaccines help reduce the likelihood of tumor resistance that can occur with single-target therapies.

Breakup by Disease Type:

Autoimmune Disease Vaccines

Addiction Vaccine

Neurological Disease Vaccine

Infectious Disease Vaccine

Others

Autoimmune disease vaccines represent the largest market segment

A detailed breakup and analysis of the market based on the disease type has also been provided in the report. This includes autoimmune disease vaccines, addiction vaccines, neurological disease vaccine, infectious disease vaccine, and others. According to the report, autoimmune disease vaccines dominates the market due to the rising prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and lupus across the globe. Additionally, these vaccines offer a potential alternative by stimulating immune tolerance, reducing the need for immunosuppression. Apart from this, they can be customized based on individual patient profiles, considering genetic and immunological factors. This aligns with the growing trend towards personalized medicine, enhancing treatment effectiveness. Apart from this, positive outcomes from clinical trials of autoimmune disease vaccines, coupled with advancements in immunology research, validate their potential to address unmet medical needs.

Breakup by Technology:

Autologous Vaccines

Allogeneic Vaccine

Autologous vaccines account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on technology. This includes autologous vaccines and allogeneic vaccine. According to the report, autologous vaccines hold the largest market share as they are custom-made for each patient using their own cells, ensuring a personalized treatment strategy that aligns with the patient's unique disease profile and immune system. Apart from this, since autologous vaccines use the original cells of patients, there is a lower risk of immune rejection or adverse reactions compared to treatments that involve foreign agents. Furthermore, they help reduce toxicity concerns associated with traditional treatments like chemotherapy by targeting disease cells while sparing healthy cells. Moreover, autologous vaccines are well-suited to address the genetic and molecular heterogeneity often found in diseases like cancer.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies.

Hospital pharmacies operate within healthcare facilities, which ensures direct access to patients undergoing treatments. They facilitate immediate availability, expert guidance, and seamless integration with medical care and aid in dispensing and administering therapeutic vaccines, especially for critical conditions requiring close medical supervision.

Retail pharmacies are widespread and easily accessible to the general population. They offer convenience and a wide range of healthcare products, including therapeutic vaccines. Additionally, they cater to diverse patient needs, making therapeutic vaccines more accessible to the masses.

Online pharmacies offer a convenient platform to purchase therapeutic vaccines remotely. They provide a wide selection, price comparisons, and home delivery, which are particularly advantageous for patients with mobility limitations or those seeking privacy.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest therapeutic vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region has a well-developed healthcare infrastructure, comprising modern hospitals, research institutions, and pharmaceutical companies, which accelerates research, development, and commercialization of therapeutic vaccines. Additionally, North America is a global hub for medical research and innovation, housing renowned universities, research centers, and biotechnology firms. Apart from this, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug and vaccine approvals. Moreover, North America has a well-established clinical trial ecosystem, which facilitates the efficient testing and validation of therapeutic vaccines. The availability of diverse patient populations and expert medical professionals expedites the trial process.

Competitive Landscape:

Companies are investing in research to identify novel antigens and develop innovative vaccine platforms, which include exploring cutting-edge technologies like mRNA-based vaccines, viral vectors, and personalized vaccine approaches. Additionally, many vaccine developers are conducting rigorous clinical trials to evaluate the safety and efficacy of their products. Furthermore, they are working closely with regulatory agencies to obtain approvals for their therapeutic vaccines. This involves compiling comprehensive data from clinical trials to demonstrate safety, efficacy, and manufacturing quality. Moreover, many leading companies are investing in infrastructure and technologies to ensure consistent and efficient vaccine production.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agenus Inc.

Argos Therapeutics Inc.

Bavarian Nordic A/S

Cel-Sci Corporation

CSL Limited

Emergent Biosolutions Inc.

GSK plc

Merck & Co. Inc.

Pfizer Inc.

Sanofi S.A.

Recent Developments:

In July 2023, Sanofi S.A. announced that it has received marketing authorization for Dupixent(R) (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis.

In August 2023, the European Commission approved Pfizer Inc's ABRYSVO(TM) to help protect infants through maternal immunization and older adults from RSV.

In August 2023, Merck & Co. Inc. announced that LYNPARZA(R) (olaparib)Plus Abiraterone and Prednisolone are approved in Japan for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Key Questions Answered in This Report

  • 1. What was the size of the global therapeutic vaccines market in 2023?
  • 2. What is the expected growth rate of the global therapeutic vaccines market during 2024-2032?
  • 3. What are the key factors driving the global therapeutic vaccines market?
  • 4. What has been the impact of COVID-19 on the global therapeutic vaccines market?
  • 5. What is the breakup of the global therapeutic vaccines market based on the type?
  • 6. What is the breakup of the global therapeutic vaccines market based on the disease type?
  • 7. What is the breakup of the global therapeutic vaccines market based on the technology?
  • 8. What are the key regions in the global therapeutic vaccines market?
  • 9. Who are the key players/companies in the global therapeutic vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Therapeutic Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Antigen Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Dendritic Cell Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Vaccine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Tumor Cell Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Autoimmune Disease Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Addiction Vaccine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disease Vaccine
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infectious Disease Vaccine
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Autologous Vaccines
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Allogeneic Vaccine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Argos Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Bavarian Nordic A/S
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Cel-Sci Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 CSL Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Emergent Biosolutions Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GSK plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co. Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Therapeutic Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Therapeutic Vaccines Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Therapeutic Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Therapeutic Vaccines Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Therapeutic Vaccines Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Therapeutic Vaccines Market: Breakup by Technology (in %), 2023
  • Figure 7: Global: Therapeutic Vaccines Market: Breakup by Distribution Channel (in %), 2023
  • Figure 8: Global: Therapeutic Vaccines Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Therapeutic Vaccines (Antigen Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Therapeutic Vaccines (Antigen Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Therapeutic Vaccines (DNA Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Therapeutic Vaccines (DNA Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Therapeutic Vaccines (Addiction Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Therapeutic Vaccines (Addiction Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Therapeutic Vaccines (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Therapeutic Vaccines (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Therapeutic Vaccines (Autologous Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Therapeutic Vaccines (Autologous Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Therapeutic Vaccines (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Therapeutic Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Therapeutic Vaccines (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Therapeutic Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Therapeutic Vaccines (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Therapeutic Vaccines (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Therapeutic Vaccines Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Therapeutic Vaccines Industry: SWOT Analysis
  • Figure 87: Global: Therapeutic Vaccines Industry: Value Chain Analysis
  • Figure 88: Global: Therapeutic Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Therapeutic Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Therapeutic Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Therapeutic Vaccines Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Therapeutic Vaccines Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 5: Global: Therapeutic Vaccines Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Therapeutic Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Therapeutic Vaccines Market: Competitive Structure
  • Table 8: Global: Therapeutic Vaccines Market: Key Players